The breakthrough marks the country’s entry into advanced gene-editing therapeutics, an area so far dominated by a handful of ...

T-cell lymphoma has remained an exceptionally challenging disease with limited therapeutic advances for far too long,” said Nicholas Siciliano, Ph.D., Chief Executive Officer of Vittoria ...

The emergence of metazoan multicellularity has captivated evolutionary cell and developmental biologists for decades. Recent advances in genome sequencing, phylogenetic comparisons, the successful ...

Beam Therapeutics will present new BEAM-101 data for sickle cell disease at EHA2025, detailing safety and efficacy in 17 patients. Beam Therapeutics Inc. has announced that it will present updated ...

SAN DIEGO--(BUSINESS WIRE)--Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that ...

Remember Biology 101? I sure do. It was the first class I had in my first semester in college at the ripe age of 18. It started at 7:30 in the morning, whether or not I did, and was taught by one of ...

The investigational therapy will be used in Kyverna's KYSA-5 Phase 1/2 open-label, multicenter study to evaluate KYV-101 in adult patients with diffuse cutaneous systemic sclerosis (scleroderma) This ...

Article XIV E.3.a of the TSSU-SFU Collective Agreement allows for up to 25% of appointments within a given department to be reserved for graduate students or postdoctoral fellows. “While priority will ...

The two articles describe the physical interactions between the retinoblastoma protein and D cyclins, a basic discovery in cell biology that has ramifications for the study of cancer. Both types of ...